Physician profile
Quasir Raza
NPI 1497846943
$10,879.04
in general payments reported to CMS, 2019-2025
64 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,686 · 2020: $1,095 · 2021: $1,932 · 2022: $2,256 · 2023: $1,545 · 2024: $1,234 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,910.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,073.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $990.06 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $807.19 | 2019-2024 | Airsupra, Farxiga, Saphnelo |
| Abbvie INC. | $767.86 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $664.27 | 2019-2024 | |
| Pfizer INC. | $539.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $433.01 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $402.08 | 2020-2025 | Freestyle Libre 3, Proclaim |
| Janssen Pharmaceuticals, INC | $398.02 | 2019-2023 | Spravato, Xarelto |
| E.R. Squibb & Sons, L.L.C. | $315.78 | 2019-2024 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $289.79 | 2021-2025 | Verquvo, Belsomra, Zerbaxa |
| Amarin Pharma, INC. | $282.36 | 2019-2021 | |
| Argenx US, INC. | $275.43 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $255.11 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $241.18 | 2020-2022 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quasir Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.